The net profit of drugmaker Glenmark Pharmaceuticals increased by 6 per cent to Rs 233.87 crore during the January-March quarter of the fiscal year 2020-21. In comparison, for the same quarter, net profit stood at Rs 220.30 crore in the fiscal year 2019-20. The company gave this information in a regulatory filing on Friday. It credited higher sales for the jump in its net profit.
Here’s a look at some other financial indicators of the drug firm:
Consolidated revenue from operations (Quarterly):
In its regulatory filing, Glenmark Pharmaceuticals revealed that for the fourth quarter of the fiscal year 2020-21, its consolidated revenue from operations came out at Rs 2859.9 crore. This is an increase from revenue generated in the previous year for the same quarter which stood at Rs 2767.5 crore.
Consolidated revenue from operations (Fiscal):
The overall revenue generated by the company in the fiscal year ending in March 2021 was Rs 10,943.9 crore. For comparison, the figure for the previous fiscal year, 2019-20, stood at Rs 10,641 crore.
Net profit (fiscal):
At the end of the fiscal year 2020-21, the net profit for the pharma company stood at Rs 970 crore, an increase from Rs 776 crore in the previous fiscal.
Dividend:
According to Glenmark, its board has recommended giving out a dividend of Rs 2.50 per share to the company’s shareholders for the financial year 2020-21.
In a statement, Glenn Saldanha, Chairman and MD of Glenmark Pharmaceuticals said, “We delivered consistent performance during the year despite operational challenges due to the COVID-19 pandemic.” Further he mentioned about the company’s leading brand, FabiFlu, and how it “led from the front in India’s fight against the pandemic.”
